An extension of the single threshold design for monitoring efficacy and safety in phase II clinical trials.
暂无分享,去创建一个
[1] Valeria Sambucini. A Bayesian predictive strategy for an adaptive two-stage design in phase II clinical trials. , 2010, Statistics in medicine.
[2] Peter F. Thall,et al. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. , 1998 .
[3] Valeria Sambucini,et al. A Bayesian predictive two‐stage design for phase II clinical trials , 2008, Statistics in medicine.
[4] J. Bernardo,et al. An introduction to Bayesian reference analysis: inference on the ratio of multinomial parameters , 1998 .
[5] Hua Jin. Alternative designs of phase II trials considering response and toxicity. , 2007, Contemporary clinical trials.
[6] J. Bryant,et al. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. , 1995, Biometrics.
[7] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[8] Byron J Gajewski,et al. Bayesian sample size calculations in phase II clinical trials using informative conjugate priors. , 2004, Controlled clinical trials.
[9] Fulvio De Santis. Sample Size Determination for Robust Bayesian Analysis , 2006 .
[10] James O. Berger,et al. Ordered group reference priors with application to the multinomial problem , 1992 .
[11] P. Thall,et al. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. , 1995, Statistics in medicine.
[12] P F Thall,et al. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Peter Walley,et al. Analysis of Clinical Data Using Imprecise Prior Probabilities , 1996 .
[14] L. Wasserman,et al. The Selection of Prior Distributions by Formal Rules , 1996 .
[15] M R Conaway,et al. Bivariate sequential designs for phase II trials. , 1995, Biometrics.
[16] Pierpaolo Brutti,et al. Robust Bayesian sample size determination in clinical trials , 2008, Statistics in medicine.
[17] Bernard Asselain,et al. Methods of joint evaluation of efficacy and toxicity in phase II clinical trials. , 2007, Contemporary clinical trials.
[18] P F Thall,et al. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. , 1998, Biometrics.
[19] David Machin,et al. Bayesian two‐stage designs for phase II clinical trials , 2002, Statistics in medicine.
[20] G. Severi,et al. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma , 2003, Cancer.
[21] M R Conaway,et al. Designs for phase II trials allowing for a trade-off between response and toxicity. , 1996, Biometrics.
[22] J. Bernardo. Reference Posterior Distributions for Bayesian Inference , 1979 .